伊马替尼
医学
髓系白血病
内科学
酪氨酸激酶抑制剂
肿瘤科
队列
甲磺酸伊马替尼
酪氨酸激酶
癌症
受体
作者
Claudia Ielo,Emilia Scalzulli,Ida Carmosino,Sara Pepe,Maria Laura Bisegna,Maurizio Martelli,Massimo Breccia
标识
DOI:10.1080/10428194.2023.2255804
摘要
The outcome of chronic myeloid leukemia (CML) patients improved in the last decade. Clinical prognostic scoring systems aim to provide information about survival in the long-term, without determining from baseline the subset of patients who require a strictly monitoring because at increased risk of failure. Imatinib, the first-generation tyrosine kinase inhibitor (TKI), is still widely used as frontline treatment: recently, the imatinib therapy failure (IMTF) score was proposed to identify the failure free survival. Aim of our study was to validate this index in a large cohort of patients treated with imatinib.
科研通智能强力驱动
Strongly Powered by AbleSci AI